Abstract
Grade IV gliomas, also known as glioblastoma multiforme (GBM), are incurable, lethal brain tumors, whose average life expectancy is around 15 months. There is a desperate need for a better understanding of the basic biology of these tumors, in order to devise novel, more specific and effective therapeutics. The handling of GBM represents a daunting challenge to clinicians, also considering the few therapeutic options available, none of which can significantly alter the inevitable lethal outcome of these tumors. Hence, the development of effective therapies would greatly benefit from the availability of in vivo GBM models that can reliably mimic the characteristics of malignant cells and the features of the human disease. Candidate new drugs have to be tested in these in vivo models by adopting settings concerning direct intra-brain delivery in order to define their overall therapeutic efficacy under clinical-like conditions. Here, we describe local intracranial delivery of drugs by osmotic mini-pumps.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSpringer Nature is developing a new tool to find and evaluate Protocols. Learn more
References
Rautioa J, Chikhale PJ (2004) Drug delivery systems for brain tumor therapy. Curr Pharm Des 10:1341–1353
Lesniak MS, Brem H (2004) Targeted therapy for brain tumours. Nat Rev Drug Discov 3:499–508
Ghersi-Egea JF, Leininger-Muller B, Cecchelli R, Fenstermacher JD (1995) Blood-brain interfaces: relevance to cerebral drug metabolism. Toxicol Lett 82-83:645–653
Kusuhara H, Sugiyama Y (2001) Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (Part 2). Drug Discov Today 6:206–212
Binda E, Visioli A, Giani F, Lamorte G, Copetti M, Pitter KL et al (2012) The EphA2 receptor drives self-renewal and tumorigenicity in stem-like tumor-propagating cells from human glioblastomas. Cancer Cell 22:765–780
Binda E, Visioli A, Giani F, Trivieri N, Palumbo O, Restelli S et al (2017) Wnt5a drives an invasive phenotype in human glioblastoma stem-like cells. Cancer Res 77:996–1007
Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH (1994) Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A 91:2076–2080
Burgess A, Hynynen K (2014) Drug delivery across the blood-brain barrier using focused ultrasound. Expert Opin Drug Deliv 11:711–721
Debinski W, Tatter SB (2009) Convection-enhanced delivery for the treatment of brain tumors. Expert Rev Neurother 9:1519–1527
Theeuwes F, Yum SI (1976) Principles of the design and operation of generic osmotic pumps for the delivery of semisolid or liquid drug formulations. Ann Biomed Eng 4:343–353
Fish RE, Brown MJ, Danneman PJ, Karas AZ (2008) American college of laboratory animal medicine. Anesthesia and analgesia in laboratory animals, 2nd edn. Academic Press, San Diego
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Binda, E., Visioli, A., Trivieri, N., Vescovi, A.L. (2019). Drug Delivery in an Orthotopic Tumor Stem Cell-Based Model of Human Glioblastoma. In: Singh, S., Venugopal, C. (eds) Brain Tumor Stem Cells. Methods in Molecular Biology, vol 1869. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-8805-1_17
Download citation
DOI: https://doi.org/10.1007/978-1-4939-8805-1_17
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-8804-4
Online ISBN: 978-1-4939-8805-1
eBook Packages: Springer Protocols